Elisavet Paplomata ABRCC-1

    Clinical Researchers Showcase Series - October 2015

    Translational Medicine Research:

 View from the Trenches Newsletter


Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted

only in a lab, to bedside clinical practice or dissemination

to population-based community interventions.

-  Source: NIH -- Read more

from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. Elisavet Paplomata, M.D.
Winship Cancer Institute

Emory University, Atlanta, GA

ABRCC Investigator

Dr. Elisavet Paplomata is an Assistant Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine.


Dr. Paplomata received her medical degree from the Cerrahpasa Faculty of Medicine, University of Istanbul, in Turkey. She trained in Obstetrics and Gynecology from 2005 to 2008 at the General Hospital of Serres in Greece, where she gained experience in cancer screening and the surgical management of benign and malignant gynecologic conditions. She then completed her residency in Internal Medicine at Texas Health Presbyterian of Dallas in Texas. She completed her fellowship in Hematology and Medical Oncology at Emory University School of Medicine while holding the position of Chief Fellow in her last year.

As a medical oncologist at the Glenn Family Breast Center at Winship Cancer Institute, she specializes in breast and gynecologic malignancies.  Dr. Paplomata's research focus is in mechanisms of resistance in breast cancer.  She has participated in basic science research and translational research on mechanisms of resistance to HER2-directed therapies and chemotherapy.

SEE the Recent OncLive.com Publication

She is currently an investigator or co-investigator in trials taking place at Emory.  Dr. Paplomata is a member of the American Society of Clinical Oncology.


About Winship Cancer Center

As the largest health care system in Georgia and the state’s ONLY National Cancer Institute-designated cancer center that brings together a full range of hospitals, clinics and local practices, Emory Healthcare is committed to providing patients and families with better, more collaborative care for all of their medical needs. The Emory Healthcare Network encompasses teams of providers at our locations across Georgia, including Emory University Hospital, Emory University Hospital Midtown, Emory University Orthopaedics & Spine Hospital, Emory Rehabilitation Hospital and the Wesley Woods Center; Emory Saint Joseph's Hospital and Emory Johns Creek Hospital; Emory Clinic; and the Emory Healthcare Network physicians, ranging from primary to specialty care providers. Learn more at: http://www.emoryhealthcare.org/about-us/index.html


for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.


To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.

The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website